KRAS and non-small cell lung carcinoma: Although monotherapy abemaciclib or palbociclib in KRAS-mutant NSCLC was ineffective [109,110], the combination of CDK 4/6 inhibitors with KRAS direct inhibitors seems promising according to preclinical data [74].